JP2014526492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526492A5 JP2014526492A5 JP2014530262A JP2014530262A JP2014526492A5 JP 2014526492 A5 JP2014526492 A5 JP 2014526492A5 JP 2014530262 A JP2014530262 A JP 2014530262A JP 2014530262 A JP2014530262 A JP 2014530262A JP 2014526492 A5 JP2014526492 A5 JP 2014526492A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- independently
- ring
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 8
- -1 Pyridinyl- Chemical group 0.000 claims description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 claims description 4
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000027004 Eosinophilic disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 2
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims description 2
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 claims description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims description 2
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 2
- 244000000010 microbial pathogen Species 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 0 CC(C)S(N1CCC(*)CC1)(=O)=O Chemical compound CC(C)S(N1CCC(*)CC1)(=O)=O 0.000 description 5
- CCBHAIKSYFMWBC-XQRVVYSFSA-N C=N/C=C(/C1CC1)\N Chemical compound C=N/C=C(/C1CC1)\N CCBHAIKSYFMWBC-XQRVVYSFSA-N 0.000 description 1
- FPSLNIKJVXOHRC-UHFFFAOYSA-N CC(C)NC(N1CCC(C)CC1)=O Chemical compound CC(C)NC(N1CCC(C)CC1)=O FPSLNIKJVXOHRC-UHFFFAOYSA-N 0.000 description 1
- LBTABEMXXIJAST-UHFFFAOYSA-N CC(CC1)CCN1S=O Chemical compound CC(CC1)CCN1S=O LBTABEMXXIJAST-UHFFFAOYSA-N 0.000 description 1
- OWCWMQJOCMEVLE-UHFFFAOYSA-N CC1CCN(CC(F)F)CC1 Chemical compound CC1CCN(CC(F)F)CC1 OWCWMQJOCMEVLE-UHFFFAOYSA-N 0.000 description 1
- JOLSRNOUXISBRG-UHFFFAOYSA-N CCC(N1CCC(C)CC1)=O Chemical compound CCC(N1CCC(C)CC1)=O JOLSRNOUXISBRG-UHFFFAOYSA-N 0.000 description 1
- SEXYCMHETBVTFR-UHFFFAOYSA-N CCCC(N1CCC(C)CC1)=O Chemical compound CCCC(N1CCC(C)CC1)=O SEXYCMHETBVTFR-UHFFFAOYSA-N 0.000 description 1
- KTBPNPCUNDUYAN-UHFFFAOYSA-N CCNC(N1CCC(C)CC1)=O Chemical compound CCNC(N1CCC(C)CC1)=O KTBPNPCUNDUYAN-UHFFFAOYSA-N 0.000 description 1
- ZBIMOFZASGTLNO-YFHOEESVSA-N CN/C=C(/c1cccc(OC)c1)\N Chemical compound CN/C=C(/c1cccc(OC)c1)\N ZBIMOFZASGTLNO-YFHOEESVSA-N 0.000 description 1
- HZFJTLFHAAKENV-UHFFFAOYSA-N COc(cccc1)c1C1=C[NH+](C=C)[N-]1 Chemical compound COc(cccc1)c1C1=C[NH+](C=C)[N-]1 HZFJTLFHAAKENV-UHFFFAOYSA-N 0.000 description 1
- BQOHGIXUJUOZGA-UHFFFAOYSA-N Cc(cc1)ccc1[S+](NC)[OH2+] Chemical compound Cc(cc1)ccc1[S+](NC)[OH2+] BQOHGIXUJUOZGA-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11181805 | 2011-09-19 | ||
| EP11181805.0 | 2011-09-19 | ||
| PCT/EP2012/068284 WO2013041497A1 (en) | 2011-09-19 | 2012-09-18 | Substituted n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526492A JP2014526492A (ja) | 2014-10-06 |
| JP2014526492A5 true JP2014526492A5 (enExample) | 2015-11-12 |
| JP6012736B2 JP6012736B2 (ja) | 2016-10-25 |
Family
ID=46875812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530262A Active JP6012736B2 (ja) | 2011-09-19 | 2012-09-18 | カテプシンｃ阻害剤である置換ｎ−［１−シアノ−２−（フェニル）エチル］−２−アザビシクロ［２．２．１］ヘプタン−３−カルボキサミド |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8999975B2 (enExample) |
| EP (1) | EP2758398B1 (enExample) |
| JP (1) | JP6012736B2 (enExample) |
| KR (1) | KR20140078626A (enExample) |
| CN (1) | CN103814028B (enExample) |
| AR (1) | AR087913A1 (enExample) |
| AU (1) | AU2012311656B2 (enExample) |
| BR (1) | BR112014006297A2 (enExample) |
| CA (1) | CA2848929A1 (enExample) |
| CL (1) | CL2014000299A1 (enExample) |
| EA (1) | EA024817B1 (enExample) |
| IL (1) | IL230820A (enExample) |
| MX (1) | MX335941B (enExample) |
| NZ (1) | NZ620208A (enExample) |
| PH (1) | PH12014500529A1 (enExample) |
| WO (1) | WO2013041497A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160029630A1 (en) | 2012-11-27 | 2016-02-04 | Basf Se | Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds and their use as fungicides |
| EP2925732A1 (en) | 2012-11-27 | 2015-10-07 | Basf Se | Substituted [1,2,4]triazole compounds |
| CN105008336A (zh) | 2012-11-27 | 2015-10-28 | 巴斯夫欧洲公司 | 取代2-[苯氧基苯基]-1-[1,2,4]三唑-1-基乙醇化合物及其作为杀真菌剂的用途 |
| WO2014140078A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c |
| EP2970252B1 (en) | 2013-03-14 | 2020-06-03 | Boehringer Ingelheim International GmbH | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| JP6437929B2 (ja) | 2013-03-14 | 2018-12-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| WO2014140075A1 (en) * | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| EP3008056B8 (en) * | 2013-06-11 | 2021-03-03 | Receptos Llc | Novel glp-1 receptor modulators |
| SG11201601150WA (en) | 2013-09-09 | 2016-03-30 | Prozymex As | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| WO2015032942A1 (en) * | 2013-09-09 | 2015-03-12 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| AR100743A1 (es) | 2014-06-06 | 2016-10-26 | Basf Se | Compuestos de [1,2,4]triazol sustituido |
| JP6529575B2 (ja) | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
| CN108047240B (zh) | 2014-09-12 | 2020-08-04 | 勃林格殷格翰国际有限公司 | 组织蛋白酶c的螺环化合物抑制剂 |
| WO2016139355A1 (en) | 2015-03-05 | 2016-09-09 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
| US10479781B2 (en) | 2015-03-05 | 2019-11-19 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors |
| HRP20250115T1 (hr) | 2018-03-01 | 2025-05-23 | Astrazeneca Ab | Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| WO2020251972A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| IL294150A (en) | 2019-12-23 | 2022-08-01 | Kymera Therapeutics Inc | Smarca joints and their uses |
| EP4182700A4 (en) | 2020-07-20 | 2024-11-13 | Insmed Incorporated | METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATMENT OF DIPETIDYL PEPTIDASE-1-MEDIATED DISEASES |
| KR20230084134A (ko) | 2020-08-26 | 2023-06-12 | 하이스코 파마수티컬즈 피티이. 엘티디. | 디펩티딜 펩티다제 1의 저해제로서 작용하는 니트릴 유도체 및 이의 용도 |
| CN114106005B (zh) * | 2020-08-26 | 2025-08-01 | 西藏海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| CA3199568A1 (en) * | 2020-12-04 | 2022-06-09 | Reistone Biopharma Company Limited | Small molecule inhibitor of cathepsin c and medicinal use thereof |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CN119156391A (zh) | 2022-06-07 | 2024-12-17 | 瑞石生物医药有限公司 | 苯并[c]色满化合物的可药用盐、其多晶型及用途 |
| CA3258114A1 (en) | 2022-06-07 | 2025-03-20 | Reistone Biopharma Company Ltd | BENZO[C]CHROMANE COMPOUND POLYMORPH, ITS PREPARATION PROCESS AND ITS USE |
| CN120112535A (zh) * | 2022-11-04 | 2025-06-06 | 南京明德新药研发有限公司 | 含氰基取代的杂环类衍生物及其制备方法 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| WO2002069901A2 (en) * | 2001-03-02 | 2002-09-12 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| JP2006527704A (ja) * | 2003-06-18 | 2006-12-07 | プロザイメックス・アクティーゼルスカブ | プロテアーゼ阻害剤 |
| TW200528440A (en) * | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| US20060223846A1 (en) * | 2005-03-08 | 2006-10-05 | Dyatkin Alexey B | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
| WO2009074829A1 (en) * | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors |
| WO2010142985A1 (en) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
-
2012
- 2012-09-14 US US13/615,781 patent/US8999975B2/en active Active
- 2012-09-18 PH PH1/2014/500529A patent/PH12014500529A1/en unknown
- 2012-09-18 BR BR112014006297A patent/BR112014006297A2/pt active Search and Examination
- 2012-09-18 EA EA201400358A patent/EA024817B1/ru not_active IP Right Cessation
- 2012-09-18 WO PCT/EP2012/068284 patent/WO2013041497A1/en not_active Ceased
- 2012-09-18 MX MX2014003080A patent/MX335941B/es unknown
- 2012-09-18 AU AU2012311656A patent/AU2012311656B2/en not_active Ceased
- 2012-09-18 JP JP2014530262A patent/JP6012736B2/ja active Active
- 2012-09-18 EP EP12759724.3A patent/EP2758398B1/en active Active
- 2012-09-18 AR ARP120103441A patent/AR087913A1/es unknown
- 2012-09-18 KR KR1020147007194A patent/KR20140078626A/ko not_active Withdrawn
- 2012-09-18 NZ NZ620208A patent/NZ620208A/en not_active IP Right Cessation
- 2012-09-18 CA CA2848929A patent/CA2848929A1/en not_active Abandoned
- 2012-09-18 CN CN201280045607.0A patent/CN103814028B/zh not_active Expired - Fee Related
-
2014
- 2014-02-05 IL IL230820A patent/IL230820A/en not_active IP Right Cessation
- 2014-02-06 CL CL2014000299A patent/CL2014000299A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526492A5 (enExample) | ||
| CA2923090C (en) | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | |
| US10220038B2 (en) | Pharmaceutical combinations | |
| AU2023286024B2 (en) | Ripretinib for treating gastrointestinal stromal tumors | |
| JP2010174019A5 (enExample) | ||
| JP2016515110A5 (enExample) | ||
| JP2017522352A5 (enExample) | ||
| KR20180054657A (ko) | Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법 | |
| US20160287605A1 (en) | Combination therapy | |
| US20160346291A1 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| JP2017537164A (ja) | リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ | |
| JP2016516020A5 (enExample) | ||
| JP2016510785A5 (enExample) | ||
| JP2010530431A5 (enExample) | ||
| JP6343285B2 (ja) | 併用療法 | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2013507415A5 (enExample) | ||
| JP2016510784A5 (enExample) | ||
| DK3027183T3 (en) | SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT | |
| AU2014310369A1 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| Shukla et al. | Novel non-biologic targets for inflammatory bowel disease | |
| AU2012332111B2 (en) | Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia | |
| BR112019020754A2 (pt) | métodos de prevenção ou tratamento de doenças oftalmológicas | |
| JP2019518736A5 (enExample) | ||
| JP6885649B2 (ja) | 統合失調症の治療のためのイロペリドン |